South and Central America Cancer Targeted Therapy Market Report Outlook (2021–2031)

Cutting-Edge Genomic Profiling and Biomarker Research

Advancements in genomic profiling and biomarker discovery are critical market drivers. Technologies such as next-generation sequencing (NGS), liquid biopsy, and molecular diagnostics enable the identification of mutations such as EGFR, ALK, HER2, BRAF, and PIK3CA. These technologies allow precision-guided therapy, enhancing efficacy and minimizing adverse effects.

The adoption of these technologies is concentrated in urban hospitals and academic medical centers in Brazil, Mexico, and Argentina, supported by local investments and international partnerships. Clinical integration of biomarker-driven therapy selection enables oncologists to administer monoclonal antibodies, tyrosine kinase inhibitors, and immune checkpoint inhibitors to patients who are most likely to benefit.

Liquid biopsy adoption allows for disease monitoring, early detection of treatment resistance, and identification of minimal residual disease, improving patient outcomes. Regional genomic initiatives and collaborations with global pharmaceutical companies accelerate the identification of targetable mutations and expand eligible patient populations.

Although cost and access challenges remain in rural areas, government programs and public-private partnerships are gradually expanding infrastructure. Increasing insurance coverage for high-cost therapies, combined with international collaborations, ensures broader adoption of precision oncology. Collectively, advancements in genomic profiling and biomarker discovery are enabling more personalized, effective, and accessible cancer treatment in South and Central America.

Personalized Therapies for Rare Genetically Driven Tumors

The expansion of targeted therapies into rare cancers represents a significant market opportunity. Historically, rare cancers have limited treatment options due to small patient populations, high development costs, and restricted access to therapies. Advances in genomic profiling allow detection of actionable mutations—such as NTRK fusions, RET rearrangements, BRAF, and FGFR alterations—enabling tumor-agnostic therapies for multiple cancer types.

Urban hospitals and oncology centers in Brazil, Mexico, and Argentina are participating in clinical trials for mutation-driven therapies, supported by partnerships with global pharmaceutical companies such as Roche, Merck, AstraZeneca, Novartis, and Bristol-Myers Squibb. Basket and umbrella trial designs allow simultaneous evaluation of therapies across rare tumor types, reducing development timelines and facilitating regulatory approvals.

Orphan drug designations and accelerated regulatory pathways in countries such as Brazil and Mexico encourage pharmaceutical companies to invest in rare cancer therapeutics. Early adoption of novel therapies in metropolitan hospitals and academic centers improves patient outcomes while demonstrating commercial potential.

Additionally, increasing awareness among clinicians, investment in molecular diagnostics, and patient access programs enhance the feasibility of introducing targeted therapies for rare cancers. As a result, companies can expand their portfolios, address unmet medical needs, and tap into new revenue streams.

The "South and Central America Cancer Targeted Therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• South and Central America Cancer Targeted Therapy market size and forecast at regional and country levels for key segments covered under the scope
• South and Central America Cancer Targeted Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• South and Central America Cancer Targeted Therapy market analysis covering key trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the South and Central America Cancer Targeted Therapy market
• Detailed company profiles, including SWOT analysis

The geographical scope of the South and Central America Cancer Targeted Therapy market report is divided into: Brazil, Argentina, Peru, Chile, and Colombia. Brazil held the largest share in 2024.

Brazil is the largest market in South and Central America, driven by a combination of high cancer prevalence, advanced healthcare infrastructure in urban areas, and a growing focus on precision medicine. Hospital pharmacies and specialized oncology centers dominate distribution, while molecular diagnostic labs facilitate biomarker-guided therapy. Public and private hospitals implement reimbursement programs, and international pharmaceutical companies frequently conduct clinical trials in urban centers to enable early access to novel therapies. Argentina, Chile, and Colombia exhibit moderate adoption, with access concentrated in metropolitan hospitals. Clinical trials and public-private partnerships help expand the availability of monoclonal antibodies, immune checkpoint inhibitors, and tyrosine kinase inhibitors.

Insurance coverage and government programs increasingly support high-cost therapies, although rural regions face access and affordability challenges. Across South and Central America, hospitals remain the dominant end users, while retail pharmacies and specialty centers facilitate access to oral targeted therapies. Multinational companies such as Roche, Merck, AstraZeneca, Novartis, and Bristol-Myers Squibb maintain strong regional presence through partnerships, clinical trial participation, and education initiatives. The region's diverse healthcare infrastructure necessitates localized strategies, combining premium adoption in urban hospitals with affordability-focused approaches in emerging areas, making it a promising market for targeted oncology therapies.

• The report includes qualitative and quantitative data in the South and Central America Cancer Targeted Therapy market across therapy type, indication, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting key trends and outlook of the South and Central America Cancer Targeted Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the South and Central America Cancer Targeted Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the South and Central America Cancer Targeted Therapy market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 11 cover South and Central America Cancer Targeted Therapy market segments by therapy type, indication, distribution channel, and geography across Brazil, Argentina, Peru, Chile, and Colombia. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Cancer Targeted Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer.

The South and Central America Cancer Targeted Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the South and Central America cancer targeted therapy market are:

• In October 2025, the FDA granted accelerated approval to sunvozertinib (Zegfrovy) for adults with locally advanced or metastatic non‑small cell lung cancer harboring EGFR exon 20 insertion mutations. This approval marks a major advance for patients with this resistant mutation subtype, for whom therapy options were previously limited.
• In April 2025, the U.S. Food and Drug Administration granted approvals for several targeted immuno‑oncology combinations, reflecting rapid clinical progress in precision cancer care. Specific approvals included nivolumab (Opdivo) plus ipilimumab (Yervoy) for unresectable or metastatic hepatocellular carcinoma and for microsatellite‑instability‑high or mismatch repair‑deficient colorectal cancer, moving beyond single‑agent use into combination strategies that harness both immune activation and targeted inhibition to improve outcomes.